While the granulocyte colony stimulating factors (G-CSF) filgrastim (Neupogen<sup>®</sup>), pegfilgrastim (Neulasta<sup>®</sup>), and sargramostim (Leukine<sup>®</sup>) are approved to increase survival in patients exposed to a myelosuppressive dose of radiation, no medical countermeasure is currently available for treatment of the thrombocytopenia that also results following radiation exposure.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.